# Key Constraints for Orally Active CNS Drugs

## Critical Physicochemical Properties

### Molecular Weight
- **CNS drugs:** ≤ 400-450 Da (mean ~305-310 Da)
- **General oral drugs:** ≤ 500 Da

### Polar Surface Area (PSA)
- **CNS drugs:** ≤ 60-90 Å² (optimal < 70 Å²)
- **General oral drugs:** ≤ 140 Å²
- *Most critical BBB penetration predictor*

### Lipophilicity (LogP)
- **CNS drugs:** ~2.0 (range 2-5)
- **General oral drugs:** 1.35-1.8

### Hydrogen Bond Donors (HBD)
- **CNS drugs:** ≤ 1 (strictly enforced)
- **General oral drugs:** ≤ 5
- *Most important differentiator between CNS and non-CNS drugs*

### Hydrogen Bond Acceptors (HBA)
- **CNS drugs:** 2-5 nitrogen/oxygen atoms
- **General oral drugs:** ≤ 10

### Basicity (pKa)
- **Basic compounds:** pKa 7.5-10.5 (no successful CNS drugs above 10.5)
- **Acidic compounds:** pKa ≥ 6.1 (essentially none below this)
- **Optimal range:** 5-10

## Critical Functional Parameters

### P-glycoprotein Efflux
- **Efflux ratio (ER) < 2.5** required
- CNS drugs show 3-fold lower P-gp liability (14.6% vs 42.2%)

### Permeability
- **> 150 nm/s** passive permeability required

### CNS MPO Score
- **≥ 4.0** indicates high CNS penetration probability
- 74% of marketed CNS drugs achieve this score

### Unbound Brain Penetration
- **Kp,uu,brain ≈ 1.0** ideal for passive diffusion

## Solubility Requirements

- **High aqueous solubility:** highest dose dissolves in ≤ 250 mL (pH 1-6.8)
- Must balance with lipophilicity for membrane penetration

## Key Takeaway

CNS drugs require **dramatically more restrictive constraints** than general oral drugs:

| Property | CNS Drugs | General Oral Drugs |
|----------|-----------|-------------------|
| PSA | ≤ 60-90 Å² | ≤ 140 Å² |
| Molecular Weight | ≤ 400-450 Da | ≤ 500 Da |
| H-Bond Donors | ≤ 1 | ≤ 5 |
| LogP | ~2.0 | 1.35-1.8 |

The **single hydrogen bond donor limit** and **PSA < 70 Å²** are the most critical distinguishing features for BBB penetration.